|
|
| | | | | | Dear colleagues,
| | | | | | | | The 14th International Symposium on Hodgkin Lymphoma, ISHL14, is approaching fast - only six weeks to go until we will welcome you in Cologne, Germany
| | | | | |
|
| | | | | | One of the scientific highlights awaiting delegates at ISHL14 is the first joint analysis of advanced-stage Hodgkin lymphoma, bringing together individual patient data from the German Hodgkin Study Group (GHSG) and the SWOG Cancer Research Network. For the first time, PET-guided BrECADD as given in HD21 and Nivolumab-AVD as given in S1826 are compared with directly, with the aim of establishing a broader evidence base for frontline treatment decisions in advanced-stage Hodgkin lymphoma.
| | | | | |
|
 |
| | | | | | Alex Herrera (City of Hope, Duarte, US) and Justin Ferdinandus (GHSG, Cologne, DE) will present and discuss the first results of this GHSG/SWOG intergroup analysis together in the “Advanced Stages” session on Sunday, October 04. Findings will be put into perspective in an expert discussion: what they mean in terms of efficacy and tolerability, and how they may inform shared decision-making with our patients. We are convinced that this will be one of the highlights of ISHL14 and look forward to discuss the data with you in Cologne.
| | | | | |
|
| | | | | | We have already received over 500 registrations. In case you have not registered yet, please use the online registration. We look forward to your registration.
| | | | | | | | | | | | | |
|
| | | | | | ISHL14 will take place from October 03 to 05, 2026 in Cologne, Germany. Please visit our website for further information.
| | | | | |
|
| | Best regards,
| | | | | | | | Peter Borchmann, MD,
Symposium Chairman | |
Paul J. Bröckelmann, MD,
Symposium Co-Chair | |
Dennis Eichenauer, MD,
Symposium Co-Chair | |
Justin Ferdinandus, MD,
Symposium Co-Chair | |
| | | | |
|
|
|
